Vevo
Ayman AlAbdallah is a Partner at Mubadala Capital, where since 2018, Ayman has focused on investments in technology sectors including healthcare, AI, and quantum computing, as well as biotech ventures. Ayman's portfolio features several notable companies, with board member roles in various firms. Prior experience includes Senior Associate in Corporate Development at Tecan, where Ayman concentrated on M&A and equity investments, an internship at OMERS Capital Markets focusing on machine learning and event-driven investing, and positions at Airo Health and Tecan Group during educational pursuits. Ayman's foundational experience includes consulting at Accenture and research at the University of Toronto's Guenther Research Group. Ayman holds a Bachelor of Applied Science in Mechanical Engineering and an MBA from the University of Toronto.
This person is not in any teams
This person is not in any offices
Vevo
1 followers
Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients. The company’s Mosaic platform is the first to make in vivo data generation scalable, with single-cell precision, to capture in vivo context of disease at the first step of drug discovery and to better represent patient diversity in drug response over current in vitro assays. Vevo is using Mosaic to build the world’s largest in vivo atlas of how drugs interact with patient cells and training AI models on its data to find novel targets and drugs undetectable by other technologies. Located in San Francisco, CA, Vevo was founded by a team of inventors and thought leaders who have discovered drugs for “undruggable” targets and invented novel methods in genomics, computational biology, and chemistry. Vevo is backed by leading investors at the intersection of life sciences and technology, including General Catalyst, Wing Venture Capital, Mubadala Capital, AIX Ventures, and Camford Capital. Learn more at www.vevo.ai.